Patent classifications
C12N15/52
RECOMBINANT MICROORGANISMS AS A VERSATILE AND STABLE PLATFORM FOR PRODUCTION OF ANTIGEN-BINDING MOLECULES
The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.
NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF OLIVETOLIC ACID AND ANALOGUES OF OLIVETOLIC ACID
The disclosure provides biosynthetic platforms that generate olivetolic acid and its analogues at high titers from microbes, and in cell free systems.
Recombinant <i>Bacillus subtilis </i>for synthesizing GDP-L-fucose and application thereof
The disclosure discloses recombinant Bacillus subtilis for synthesizing guanosine diphosphate fucose and a construction method and application thereof. The recombinant Bacillus subtilis is obtained by intensively expressing guanylate kinase and nucleotide diphosphokinase genes and expressing exogenous fucokinase and phosphate guanylyltransferase genes in a genome of Bacillus subtilis 168. According to the disclosure, a bacterial strain for synthesizing the guanosine diphosphate fucose is obtained by reconstructing the Bacillus subtilis 168, with a volume of intracellular accumulation up to 196.15 g/L. According to the disclosure, by intensively expressing the guanylate kinase and nucleotide diphosphokinase genes, and enhancing the supply of intracellular GDP-L-fucose composition cofactors, the synthesis of the guanosine diphosphate fucose is promoted. The construction method for the recombinant Bacillus subtilis of the disclosure is simple and convenient to use, thus having good application prospects.
LACHNOSPIRACEAE BACTERIUM ND2006 CAS12A MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME
This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.
EXPRESSION OF ELECTRICALLY CONDUCTIVE PROTEIN NANOWIRES IN ESCHERICHIA COLI
The present invention provides, in various embodiments, genetically modified aerobic bacteria, polynucleotides and methods for expressing and/or harvesting electrically conductive protein nanowires (e-PNs). The present invention also provides e-PNs produced using the genetically modified aerobic bacteria, polynucleotides and methods.
EXPRESSION OF ELECTRICALLY CONDUCTIVE PROTEIN NANOWIRES IN ESCHERICHIA COLI
The present invention provides, in various embodiments, genetically modified aerobic bacteria, polynucleotides and methods for expressing and/or harvesting electrically conductive protein nanowires (e-PNs). The present invention also provides e-PNs produced using the genetically modified aerobic bacteria, polynucleotides and methods.
PRODUCTION OF GPP AND CBGA IN A METHYLOTROPHIC YEAST STRAIN
This invention is an improved method of robust and scalable production of precursors of active cannabinoids, including geranyl pyrophosphate (GPP) and/or cannabigerolic acid (CBGA), in a methylotrophic yeast host cell. The improved methods incorporate a polypeptide encoding an Erg20 variant (F98W/N128W) into a methylotrophic yeast host cell, for example Pichia pastoris (Komagataella phaffii), that biases the natural production of FPP and GPP towards GPP, a precursor to the intermediate CBGA, crucial to the synthesis of active cannabinoids.
NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
Disclosed are novel nitrated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The nitrated psilocybin derivative compounds may be chemically synthesized or biochemically synthesized in host cells.